TrialTracker_MD said:CRP reduction on cardiovascular risk — this is the lab result that excites me most: Baseline hsCRP: 8.0 mg/L (high cardiovascular risk) Month 6 hsCRP:…
NNT calculation for cardiovascular risk clinical endpoints: NNT = 1/ARR (absolute risk reduction).
From SELECT trial: MACE at 39 months — 6.5% semaglutide vs 8.0% placebo. ARR = 1.5%. NNT = 67 over 3.3 years.
Compare to established therapies:
| Intervention | NNT | Timeframe |
|---|---|---|
| Semaglutide (MACE) | 67 | 3.3 years |
| Statins primary prevention (MI) | ~100 | 5 years |
| Aspirin secondary prevention | ~77 | 2 years |
These NNTs are clinically meaningful and comparable to accepted cardiovascular interventions.
marco_milano said:Senior perspective on cardiovascular risk: I'm 67 years old and started this journey skeptically.
Saving this. It is the first explanation that did not require me to already understand it. Taking it to my next appointment.
TrialTracker_MD said:CRP reduction on cardiovascular risk — this is the lab result that excites me most: Baseline hsCRP: 8.0 mg/L (high cardiovascular risk) Month 6 hsCRP:…
Metabolic syndrome resolution on cardiovascular risk: I went from meeting 3 of 5 diagnostic criteria to meeting ZERO after 11 months of treatment.
The 5 criteria (and my journey):
- Waist circumference: 50" → 36" ✅ Resolved
- Triglycerides: 270 → 95 ✅ Resolved
- HDL: 34 → 52 ✅ Resolved
- Blood pressure: 140/92 → 118/72 ✅ Resolved
- Fasting glucose: 120 → 86 ✅ Resolved
Metabolic syndrome reversal is, in my view, the most medically significant outcome of GLP-1 therapy.
PeptideDetective — Independent Peptide Analytics
Community-driven peptide testing and vendor rating platform. Transparent results. Unbiased analysis. Trusted by thousands.
View ResultsFranDenver said:Prescribed on cardiovascular grounds rather than for weight, and almost everything written for patients assumes the opposite.
Lp(a) and cardiovascular risk: a nuance that matters. Unlike most lipid markers, Lp(a) is 90%+ genetically determined and doesn't really change with weight loss or GLP-1 therapy.
My Lp(a) has remained at 74 nmol/L across all time points. If yours is elevated (>50 nmol/L), you need additional risk mitigation strategies regardless of your GLP-1 response. Don't assume your medication is covering all cardiovascular risk factors.